Although several studies have described CD123 expression in large cohorts that included NPM1mut patients, no study had been designed to specifically analyze this AML subgroup or to compare CD123 fluorescence intensities between bulk AML cells and the CD34+CD38− population [13,15,19]. This evidence concerns the gene CD34 and acute myeloid leukemia.